# Why Does Aspirin Fail in Secondary Cerebrovascular Prevention? A Multicenter Prospective Case - Control Study

> **NCT05247931** · — · UNKNOWN · sponsor: **Fadoi Foundation, Italy** · enrollment: 100 (estimated)

## Conditions studied

- Cerebrovascular Disease

## Interventions

- **DIAGNOSTIC_TEST:** TXB2 assay of serum , and 11-dehydro-TXB2 assay of urine

## Key facts

- **NCT ID:** NCT05247931
- **Lead sponsor:** Fadoi Foundation, Italy
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-07
- **Primary completion:** 2022-04-30
- **Final completion:** 2022-04-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05247931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05247931, "Why Does Aspirin Fail in Secondary Cerebrovascular Prevention? A Multicenter Prospective Case - Control Study". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05247931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*